Keywords
central nervous system
meninges
How to Cite
Abstract
Primary central nervous system lymphoma (PCNSL), a subtype of non-Hodgkin lymphoma (NHL), is a rare, brain, spinal cord, cerebrospinal fluid (CSF), cranial nerves and/or eyes restricted, with different prognostic and treatment implications compared to other brain tumors. Leptomeningeal involvement is present in approximately 15 to 20 percent of the cases. These patients are usually asymptomatic and may have no evidence of abnormal leptomeningeal enhancement on magnetic resonance imaging (MRI) of the brain and spine. Basic CSF parameters are usually, but not always, abnormal, including a high protein level in 75 percent of cases and an elevated cell count in 50 percent. The symptoms of primary leptomeningeal lymphoma are highly variable. Patients may have cranial neuropathies, encephalopathy, radicular symptoms due to involvement of the spinal nerve root and/or hydrocephalus. We present the case of a patient with immunocompetent chronic inflammatory demyelinating polyneuropathy of months of evolution with subsequent diagnosis of primary CNS lymphoma with leptomeningeal involvement.
References
Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010 Apr;9(4):402-12. doi: 10.1016/S1474-4422(10)70041-7.
Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988 Jun;68(6):835- 53. doi: 10.3171/jns.1988.68.6.0835.
Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 Nov;50(11):621-37.
Silwal A, Pitt M, Phadke R, Mankad K, Davison JE, Rossor A, DeVile C, Reilly MM, Manzur AY, Muntoni F, Munot P. Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neuromuscul Disord. 2018 Sep;28(9):757-765. doi: 10.1016/j.nmd.2018.06.001.
Van den Bergh PYK, van Doorn PA, Hadden RDM et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. J Peripher Nerv Syst. 2021; 26(3): 242–268. https://doi.org/10.1111/jns.12455
Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011 Jul 21;118(3):510-22. doi: 10.1182/blood-2011-03-321349.
Ferreri AJ, Cwynarski K, Pulczynski E et al; International
Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomization of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3.
Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2025 A Quesada, MJ Mallorquin, G Castelli, S Lopresti, D Villalba